Search Results
ASH2014: Christoph Röllig - SAL-Soraml Trial
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
ASH2014: Wendy Stock - U.S. Intergroup Trial C10403 in ALL
Röllig: Sorafenib for Acute Myeloid Leukemia
Phase II trial of sorafenib plus standard therapy in newly diagnosed acute myeloid leukaemia
Christoph Röllig on AML research in Dresden, Germany
ASH 2014: Ask the experts Q&A session 2
Factors that contribute to treatment decisions in acute myeloid leukemia
Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML
AML treatment: what does the data say?
Christoph Röllig | EHA 2018 | 90 mg vs. 60 mg daunorubicin in 7+3 standard induction for ND AML
Factors that contribute to treatment decisions in acute myeloid leukemia
